Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation (Nasdaq: OPRX) regularly issues news and updates about its healthcare technology platform, partnerships, and financial performance. Company press releases describe OptimizeRx as a healthcare technology company that helps life science brands reach and engage healthcare professionals (HCPs) and patients through AI-driven tools, point-of-care integrations, and proprietary audience data.
News items for OptimizeRx often cover collaborations with other data and media companies, such as integrations that connect its patented Micro-Neighborhood® audience data with external identity graphs or out-of-home advertising networks. These announcements explain how the company’s privacy-safe, deterministic audience cohorts are used to support omnichannel and direct-to-consumer campaigns, improve audience quality, and reduce audience loss during onboarding and activation.
Investors and observers will also find earnings releases and guidance updates among OptimizeRx news. These releases include discussions of revenue trends, profitability metrics, key performance indicators related to top pharmaceutical manufacturers, and commentary from management about the company’s progress toward its strategic objectives. Conference call announcements and investor conference participation are also common topics, providing details on how to access management’s discussions of quarterly and annual results.
Additional news highlights may include expansions of the company’s in-workflow point-of-care network through new or renewed agreements with electronic health record (EHR) vendors, e-prescribing platforms, and health systems access partners. Leadership updates and organizational changes are reported through current reports and associated press releases, outlining adjustments in executive roles and governance. For anyone following OPRX, this news page serves as a central source for official company communications on partnerships, technology developments, financial results, and corporate governance.
OptimizeRx Corp. (Nasdaq: OPRX) reported a robust performance for Q4 2020 with revenues soaring 123% to $16.4 million, driving a full-year revenue increase of 76% to $43.3 million. The company's gross profit for Q4 rose 92% to $8.6 million, and GAAP net income was $1.4 million or $0.08 per diluted share. A significant cash infusion of $71 million from an equity offering supports future growth. With a pipeline exceeding $180 million and recognition from Deloitte as a top growth company, OptimizeRx plans for ongoing expansion and innovation in 2021.
OptimizeRx Corporation (Nasdaq: OPRX) announced that Angelo Campano, its senior vice president, has been named to MM+M’s 2021 ‘40 Under 40’ list for his notable contributions to healthcare marketing. This recognition highlights young leaders who have driven growth in the industry amid challenging conditions. Campano brings over 18 years of experience in digital channel partnerships, collaborating with 245 EHR platforms and 100 specialty pharma partners. His leadership has earned him accolades, including PM360’s ELITE Innovator Award in 2017.
OptimizeRx Corporation (Nasdaq: OPRX) will host a conference call on February 24, 2021, at 4:30 p.m. ET to discuss its fourth-quarter and full-year 2020 results. The company anticipates reporting record revenue exceeding $16 million, reflecting a 117% increase year-over-year, alongside positive GAAP net income. This growth is attributed to the expanded use of its digital health solutions by life science companies, boosting provider and patient engagement. Full financial results will be disclosed prior to the call.
OptimizeRx Corporation (Nasdaq: OPRX) has been invited to present at the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021. CEO William Febbo is set to present on February 25 at 5:00 p.m. Eastern time, along with virtual meetings with analysts and investors. The firm reported record preliminary results for Q4 and full year 2020, expecting a 117% revenue increase to $16 million for Q4, and a 75% increase to $43 million for the full year. These gains reflect increased engagement among life science companies using OptimizeRx’s digital health network.
OptimizeRx Corporation (Nasdaq: OPRX) has priced an underwritten public offering of 1,325,000 shares at $49.50 each, aiming for gross proceeds of approximately $65.6 million. Underwriters hold a 30-day option for an additional 198,750 shares. Closing is expected around February 11, 2021. Proceeds will be used for general corporate purposes, potentially including future acquisitions, although no immediate agreements are in place. The offering is conducted under an effective shelf registration statement with the SEC, ensuring compliance and transparency for investors.
OptimizeRx Corporation (Nasdaq: OPRX) announced the commencement of an underwritten public offering of its common stock. The company may grant underwriters a 30-day option to purchase an additional 15% of the shares being offered. Proceeds from the offering will be utilized for general corporate purposes, potentially including future acquisitions. The offering is subject to market conditions, with no guarantees on completion or terms. A registration statement has been filed with the SEC and is effective as of February 8, 2021.
OptimizeRx Corp. (Nasdaq: OPRX) announced record preliminary financial results for the fourth quarter and full year ended December 31, 2020. The company expects fourth-quarter revenue to reach approximately $16 million, a 117% increase year-over-year, alongside positive GAAP net income. For the full year, revenue is projected at $43 million, up 75%. Strong growth is attributed to increased demand for digital health solutions from life science companies. OptimizeRx aims for continued expansion, reporting a robust sales pipeline of $170 million heading into 2021.
OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, announced its upcoming presentation at the B. Riley Securities 2021 Vision Day Conference on January 28, 2021, at 1:30 p.m. Eastern time. CEO William Febbo will discuss the company's expansive digital health platform, which connects life science companies with patients' care journeys, facilitating medication affordability and adherence. The event will feature a live webcast and is expected to address OptimizeRx's growth opportunities and new digital health solutions.
OptimizeRx Corp. (Nasdaq: OPRX) has been invited to present at the H.C. Wainwright BioConnect Conference, taking place virtually from January 11-14, 2021. The presentation will be available on-demand starting at 6:00 a.m. ET on January 11 and can be accessed via the conference portal and OptimizeRx’s investor relations page. CEO William Febbo will hold one-on-one virtual meetings with institutional analysts and investors, highlighting the company's expanding market due to new digital health solutions. OptimizeRx reported $34.3 million in trailing revenue for the 12 months ending September 30, 2020, marking a 44% increase from the previous year.
Summary not available.